Bank of Montreal Can Sells 50,354 Shares of Illumina, Inc. (NASDAQ:ILMN)

Bank of Montreal Can lessened its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 33.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 100,900 shares of the life sciences company’s stock after selling 50,354 shares during the quarter. Bank of Montreal Can owned approximately 0.06% of Illumina worth $13,483,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Golden State Wealth Management LLC acquired a new position in shares of Illumina during the 4th quarter worth approximately $32,000. Versant Capital Management Inc boosted its position in Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 146 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Illumina in the fourth quarter valued at $45,000. Assetmark Inc. increased its holdings in shares of Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after purchasing an additional 296 shares during the last quarter. Finally, Lee Danner & Bass Inc. bought a new position in shares of Illumina in the fourth quarter valued at about $48,000. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on ILMN shares. Stephens reiterated an “overweight” rating and issued a $156.00 price target on shares of Illumina in a research note on Tuesday, March 11th. Hsbc Global Res lowered Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. Piper Sandler lifted their price target on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Guggenheim decreased their price objective on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and dropped their target price for the stock from $177.00 to $140.00 in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and an average price target of $138.70.

Illumina Stock Performance

NASDAQ:ILMN opened at $74.78 on Friday. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $11.85 billion, a PE ratio of -9.74, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The stock’s 50-day simple moving average is $88.58 and its 200 day simple moving average is $122.32.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.